Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease

Acta Haematologica

Volumn 112, Issue 3, 2004, Pages 141-147

  Aversa, Savina M L ^a   Salvagno, Luigi ^b   Sorarù, Mariella ^c   Mazzarotto, Renzo ^a   Boso, Caterina ^a   Gaion, Fernando ^c   Chiarion Sileni, Vanna ^a   De Franchis, Giuseppe ^a   Favaretto, Adolfo G ^a   Crivellari, Gino ^a   Banna, Giuseppe Luigi ^a   Sotti, Guido ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Vittorio Veneto Hospital   (Italy)

^c Civic Hospital   (Italy)

Author keywords

Advanced stages; Combined modality therapy; Hodgkin's disease

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; COTRIMOXAZOLE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; OMEPRAZOLE; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HODGKIN DISEASE; HUMAN; LEUKEMIA; MALE; MEDICAL ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 4644225088     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079725     Document Type: Article

References (23)

1. De Vita VJ, Simon RM, Hubbard SM: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-595.
2. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe E, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
3. Bonadonna G., Zucali R, Monfardini S, De Lena M, Uslenghi C: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-259.
4. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
5. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995;13:1080-1088.
6. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996;7(suppl 4):105-108.
7. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease: Staging classification. Cancer Res 1976;38:288-305.
8. Kaplan EL, Meier P: Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin' s disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
10. Clough KH, Goffined F, Labib A, Renolleau C, Campana F, de la Rochefordière A, Durand JC: Laparoscopic unilateral ovarian transposition prior to irradiation: Prospective study of 20 cases. Cancer 1996;2638-2645.
11. Aisenberg AC: Problems in Hodgkin's disease management. Blood 1999;93:761-779.
12. Schmoll H: Review of etoposide single-agent activity. Cancer Treat Rev 1982;9:21-30.
13. Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclaver D, Nister-Backes H, Sieber M, Smith K, Tesch H, Geilen W: Further chemotherapy versus low-dose involved field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. German Hodgkin's Study Group (GHSG). Ann Oncol 1995;6:901-910.
14. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Study Group. Ann Oncol 1997;8:1-6.
15. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M, for the German Hodgkin's Lymphoma Study Group: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
16. Radford JA, Crowter D: Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: Results of pilot study in 20 patients. Ann Onc 1991;2:5056-5059.
17. Radford JA, Rohatiner AZS, Dunlop DJ: Preliminary results of a four-centre randomized trial comparing weekly VAPEC-B chemotherapy with ChlVPP/EVA hybrid regimen in previously untreated patients (abstract 12). Proc Am Soc Clin Oncol 1997;16.
18. Horning SJ, Williams J, Bartlett NL, Bennet JM, Hoppe RT, Neub Cassileth P: Assessment of the Stanford V Regimen and consolidate radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 2000;18:972-980.
19. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
20. Chisesi T, Federico M, Levis A, Lambertenghi Deliliers G, Gobbi PG, Santini G, Luminari S, Brugiatelli M: ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: Results of a randomized trial. Ann Oncol 2002;13(suppl 1):102-106.
21. Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Myers J, Caravelli J, Clarkson BD, Fuks Z: Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combination. J Clin Oncol 1991;9:2193-2201.
22. Young RC, Canellos GP, Chabner BA, Hubbard SM, De Vita VT Jr: Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978;42(suppl 2):1001-1007.
23. Loeffler M, Brostenau O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompdon E, Wiernik P: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998;16:818-829.